Gilead pays $400mm up front, plus earn-outs, to buy Nimbus Apollo and its ACC program for NASH
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Acquisition of Private Biotech
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.